These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 15632170)

  • 1. The E46K mutation in alpha-synuclein increases amyloid fibril formation.
    Greenbaum EA; Graves CL; Mishizen-Eberz AJ; Lupoli MA; Lynch DR; Englander SW; Axelsen PH; Giasson BI
    J Biol Chem; 2005 Mar; 280(9):7800-7. PubMed ID: 15632170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
    J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.
    Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M
    FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.
    Fredenburg RA; Rospigliosi C; Meray RK; Kessler JC; Lashuel HA; Eliezer D; Lansbury PT
    Biochemistry; 2007 Jun; 46(24):7107-18. PubMed ID: 17530780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-silico investigation of protective mechanisms of crocin against E46K α-synuclein amyloid formation.
    Ghasemi Tigan M; Ghahghaei A; Lagzian M
    Mol Biol Rep; 2019 Aug; 46(4):4279-4292. PubMed ID: 31111370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
    Sode K; Usuzaka E; Kobayashi N; Ochiai S
    Biochem Biophys Res Commun; 2005 Sep; 335(2):432-6. PubMed ID: 16081040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization.
    Waxman EA; Mazzulli JR; Giasson BI
    Biochemistry; 2009 Oct; 48(40):9427-36. PubMed ID: 19722699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alpha-synuclein mutation E46K promotes aggregation in cultured cells.
    Pandey N; Schmidt RE; Galvin JE
    Exp Neurol; 2006 Feb; 197(2):515-20. PubMed ID: 16325180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties.
    Ulrih NP; Barry CH; Fink AL
    Biochim Biophys Acta; 2008 Oct; 1782(10):581-5. PubMed ID: 18692132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of amino acid substitution in the imperfect repeat sequences of alpha-synuclein on fibrillation.
    Harada R; Kobayashi N; Kim J; Nakamura C; Han SW; Ikebukuro K; Sode K
    Biochim Biophys Acta; 2009 Oct; 1792(10):998-1003. PubMed ID: 19596443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC; Conway KA; Lansbury PT
    Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
    Ghee M; Melki R; Michot N; Mallet J
    FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
    Cohlberg JA; Li J; Uversky VN; Fink AL
    Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
    Kessler JC; Rochet JC; Lansbury PT
    Biochemistry; 2003 Jan; 42(3):672-8. PubMed ID: 12534279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic insight into the relationship between N-terminal acetylation of α-synuclein and fibril formation rates by NMR and fluorescence.
    Kang L; Janowska MK; Moriarty GM; Baum J
    PLoS One; 2013; 8(9):e75018. PubMed ID: 24058647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein.
    Zibaee S; Jakes R; Fraser G; Serpell LC; Crowther RA; Goedert M
    J Mol Biol; 2007 Nov; 374(2):454-64. PubMed ID: 17936783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural features of α-synuclein amyloid fibrils revealed by Raman spectroscopy.
    Flynn JD; McGlinchey RP; Walker RL; Lee JC
    J Biol Chem; 2018 Jan; 293(3):767-776. PubMed ID: 29191831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.